Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Magnetics Combidex

Executive Summary

Magnetic resonance imaging contrast agent is "approvable" at FDA for diagnosis of lymph node disease, but not for a second indication for imaging of the liver and spleen. The company will meet with FDA to clarify the agency's questions raised in the June 21 letter. The company is seeking a partner to market Combidex to oncologists, radiologists and surgeons. The NDA was submitted Dec. 21, 1999

You may also be interested in...



Combidex May Require More Studies Following Negative Committee Review

Advanced Magnetics' imaging agent Combidex may require additional study following a negative advisory committee review

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel